ELOXX PHARMACEUTICALS INC - ELOX STOCK NEWS

Eloxx Pharmaceuticals (NASDAQ: ELOX) reported significant advancements in their clinical pipeline, targeting rare diseases. The company anticipates topline data from Phase 2 trials in cystic fibrosis and Alport syndrome by Q3 2022. Additionally, they are set to file IND applications for ELX-02 and ZKN-013 targeting various conditions by Q4 2022. Financially, Eloxx experienced a net loss of $10.6 million for Q2 2022, an improvement from $36.1 million in the same quarter last year. Cash reserves are projected to sustain operations through Q4 2023.

Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the appointment of Lindsay Androski, JD, MBA, to its board of directors, alongside her role in the Audit and Compensation Committees. This follows the departure of several board members including Gadi Veinrib and Ran Nussbaum. Androski, an experienced biotech executive from Roivant Social Ventures, aims to enhance Eloxx's focus on genetic therapies for rare diseases. The board restructuring supports the company's strategic transformation initiated with the Zikani acquisition in April 2021.

Eloxx Pharmaceuticals (NASDAQ: ELOX) announced a funding award of up to $15.9 million from the Cystic Fibrosis Foundation for its ELX-02 clinical program targeting Class 1 cystic fibrosis. Phase 2 trial results are expected by mid-2022. The company also plans to expand ELX-02's application to Alport syndrome, initiating a Phase 2 trial in late 2022. Financially, Eloxx incurred a net loss of $11.6 million for Q1 2022, with R&D expenses rising to $7.9 million. Cash reserves are anticipated to last until mid-2023.

Eloxx Pharmaceuticals (ELOX) announced a funding award of up to $15.9 million from the Cystic Fibrosis Foundation for its ELX-02 clinical development in treating cystic fibrosis (CF). The Phase 2 trial results are expected in mid-2022. The company is extending its pipeline to include Alport syndrome and plans to start proof-of-concept trials later in 2022. In preclinical studies, ZKN-013 showed promising results for treating recessive dystrophic epidermolysis bullosa and familial adenomatous polyposis. Financial results reveal a net loss of $12.1 million for Q4 2021.

Eloxx Pharmaceuticals (ELOX) has expanded its ELX-02 program to target Alport syndrome, a rare kidney disease caused by mutations in collagen genes. The initiation of a proof-of-concept clinical trial is expected in the second half of 2022, assessing up to eight patients with nonsense mutations. ELX-02 has shown promise in preclinical studies, demonstrating significant readthrough in COL4A5 mutations. Topline results from the trial are anticipated in the first half of 2023, marking a potential breakthrough in treating this underserved patient population.

Eloxx Pharmaceuticals (NASDAQ: ELOX) announced a Therapeutic Development Award of up to $15.9 million from the Cystic Fibrosis Foundation to support its ELX-02 clinical program. This funding builds on prior support and is contingent on achieving specific clinical milestones. The Phase 2 trial combines ELX-02 with ivacaftor, targeting Class 1 CF patients with nonsense mutations, a group with no current treatment options. Management expects topline results by mid-2022, along with a cash runway extension into Q2 2023. ELX-02 has Fast Track and Orphan Drug designations from the FDA.

ELX-02, administered at 1.5mg/kg/day, showed a significant mean reduction of 5.4mmol/L in sweat chloride levels, indicating potential CFTR activity restoration in cystic fibrosis patients. The results support moving ELX-02 into Phase 3 trials. The FDA has granted Fast Track and Orphan Drug Designations for ELX-02. Additionally, the company has started a Phase 2 expansion for ELX-02 combined with ivacaftor, with results anticipated by mid-2022. Eloxx aims to explore inhaled delivery of ELX-02 to enhance efficacy.

Eloxx Pharmaceuticals (NASDAQ: ELOX) reported its Q3 2021 results, posting a net loss of $9.9 million, up from $6.6 million in Q3 2020. The company is progressing with its Phase 2 ELX-02 clinical trials for cystic fibrosis, expecting data in late 2021. ELX-02 received FDA Fast Track designation, highlighting its potential for serious medical needs. Eloxx entered a debt facility with Hercules Capital for up to $30 million, drawing an initial $12.5 million. As of September 30, 2021, cash reserves stood at $52.4 million, projected to last through Q1 2023.

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) will host an Investor and Analyst call on October 12, 2021, featuring Dr. Eitan Kerem, a prominent cystic fibrosis (CF) expert. The call aims to provide updates on the company’s CF programs as data from ongoing Phase 2 trials are expected in Q4 2021. The call is scheduled for 10:00 a.m. ET, with both domestic and international dial-in options available. The event will be webcast live and accessible on the company's website, with a replay available for 30 days afterwards.